Skip to main content
CGC logo

CGC · Canopy Growth Corp

Track CGC — free
$0.56 +0.00 (+0.46%)
Market Cap
$237.59M
Shares
423.35M
Volume · Nov 13 2.74M Avg daily vol (3M) 2.81M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.56 Open$0.55 Day$0.54–0.58 52W close$0.56–1.92 Avg vol 30d2.7M Short int31.6M · 7.5% of shares · 16.5d Short vol48% Last earningsNov 6, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 6

Up next

Feb 5, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 6
Current report 8-K
Revenue rises 22% as international cannabis grows 141%

Canopy Growth reported $81.4M in Q2 FY2027 net revenue, up 22%, with international markets cannabis revenue rising 141% to $12.3M. Cannabis segment revenue reached $66.2M, up 30%, while adjusted EBITDA loss improved to $2.9M.

Financial results
5 source passages
Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced its financial results for the three months ended September 30, 2026 ("Q2 FY2027"). Consolidated net revenue of $81.4M in Q2 FY2027 increased by 22% compared to the three months ended September 30, 2025 (“Q2 FY2026”). Cannabis net revenue was $66.2M in Q2 FY2027, an increase of 30% versus the prior-year period. International markets cannabis net revenue of $12.3M in Q2 FY2027 increased 141% as compared to $5.1 million in Q2 FY2026, primarily due to strong sales in Europe, specifically in Germany and Poland. Adjusted EBITDA loss for Q2 FY2027 was $2.9M, an improvement of $0.2M or 6% compared to Q2 FY2026, primarily attributable to revenue growth across the Cannabis segment and continued cost savings, partially offset by the reduction in the VAC reimbursement rate available for medical cannabis. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2027 Q2, ended Sep 30
Canopy USA deconsolidated, leaving indirect U.S. market exposure

Canopy Growth deconsolidated Canopy USA effective April 30, 2024 and retains a non-controlling interest in the independently operated company, which holds interests in Acreage, Wana and Jetty.

Revenue 81.37M CAD ▲ 22.0% Net loss 40.69M CAD Diluted EPS -0.10 CAD
Read from the MD&A section
6 source passages
As of April 30, 2024, Canopy Growth has deconsolidated the financial results of Canopy USA and has a non-controlling interest in Canopy USA as of such date. Canopy USA was determined to be a variable interest entity pursuant to ASC 810 - Consolidations (“ASC 810”). Canopy USA and certain entities controlled by Canopy USA (the “Canopy USA LPs”) currently hold an ownership interest in the following assets, among others: Wana – Canopy USA holds 100% of the membership interests of Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana”), a leading cannabis edibles brand in North America. Jetty – Canopy USA holds approximately 77% of the shares of Jetty, a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Acreage – Canopy USA holds 100% of the issued and outstanding shares of Acreage, a vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S., including New Jersey and New York. Open the document at this passage
Oct 23
Current report 8-K
Shareholder vote results

At its October 23, 2026 annual meeting, Canopy Growth shareholders elected five directors, appointed MNP, and approved a share consolidation at a Board-determined ratio ranging from one post-consolidation share for every five to fifteen outstanding pre-consolidation shares.

Oct 16
Proxy statement DEFA14A
Proxy statement

Canopy Growth received a Nasdaq notice on October 14, 2026 that its common shares no longer comply with the $1.00 Minimum Bid Price Requirement and has until April 12, 2027 to regain compliance, with a Share Consolidation proposal up for vote at the reconvened Annual Meeting on October 23, 2026.

Oct 16
Current report 8-K Events of Oct 14
Delisting notice or listing transfer

Canopy Growth Corporation received notice from Nasdaq on October 14, 2026 that it is not in compliance with Nasdaq Listing Rule 5450(a)(1), as its common shares traded below $1.00 for 30 consecutive business days, giving it until April 12, 2027 to regain compliance.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$222.23M
Trailing 12 months
Net income (TTM)
−$194.29M
Trailing 12 months
Revenue growth YoY
+22.0%
Year over year
Operating margin
-54.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$52.02M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+54.4%
Year over year · more shares
Price change (1Y)
-49.0%
Trailing year
Short interest
7.5%
Latest settlement · 16.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −42%
below
Price vs 50-day avg −30%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −21%
trailing
6-month return −47%
trailing
YTD return −51%
this year
Relative strength −47%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
199 of 221 funds reported for Sep 30 · net -2.4M sh shares · +18 new
Insider flow Distributing
Net -$87.2K over 90 days · 100% sells
Short interest Falling
7.47% of shares out · ▼ -0.1% MoM · 16.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
221 holders — near 3-yr low, contrarian setup
Squeeze score 62
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −71%
past year
ATR 8.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 7, 2026
Synergies run rate · within 18 months of the March closing of the MTL transaction $10M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−42% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
199 of 221 funds reported for Sep 30 · net -2.4M sh shares · +18 new
Insider flow Distributing
Net -$87.2K over 90 days · 100% sells
Short interest Falling
7.47% of shares out · ▼ -0.1% MoM · 16.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
221 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $2
vs 200-day avg -42% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
adjusted gross margin for the segment non-GAAP 29% Q2 FY2027 —
Adjusted EBITDA non-GAAP -3.24M Three months ended June 30 —
Adjusted EBITDA loss non-GAAP $3.2M the first quarter of fiscal 2027 filing —
Cannabis segment gross margin percentage 22% the three months ended June 30, 2026 filing —
Free cash flow non-GAAP -25.75M Three months ended June 30 —
GAAP → non-GAAP reconciliation
GAAP Net cash used in operating activities -25.01M
-737K Purchases of and deposits on property, plant and equipment
= Free cash flow -25.75M
Gross margin percentage 27% the three months ended June 30, 2026 filing —
Storz & Bickel segment gross margin percentage 48% the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CGC
Canopy Growth Corp
this stock
$237.59M -50.8% — — 7.5%
TAK
Takeda Pharmaceutical Co Ltd
$68.47B +37.5% — — 0.1%
GALDY
Galderma Group AG
$53.23B +10.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$51.92B +42.6% +4.3% 101.1 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
214
% held
6.4%
Reported
199 of 221
Top holder
Tidal Investments LLC
Held Float
View
Held by Funds
Fund positions
16
View
Short & Settlement
Short Interest Falling
Shares short
31.6M
Days to cover
16.5d
Change
-16.0K sh
View
Short Volume
Short vol %
48%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
27.5K
Value
$20.9K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
66.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$87.2K
Buyers / Sellers
0 / 6
Buyers Sellers
View
Congressional Trades Buy
Member
John A. Yarmuth
Amount
$1.0K–$15.0K
Traded
Feb 12, 2021
View
Financials
Financials
Revenue (FY)
CAD 284.6M
Net income (FY)
$-189.0M
EPS diluted
CAD -0.88
View
Buybacks
Authorized
shares 10.4M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 6, 2026
This year
27

Canopy Growth reported $81.4M in Q2 FY2027 net revenue, up 22%, with international markets cannabis revenue rising 141% to $12.3M. Cannabis segment revenue reached $66.2M, up 30%, while adjusted EBITDA loss improved to $2.9M.

View
Earnings & Events
Webcasts
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
Canopy Growth Reports Second Quar…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
CGC -13.9% -21.3% -46.6% -14.0% -50.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -16.5% -20.1% -47.1% -13.8% -61.4%

Capital returns

Buyback program · as of Apr 2, 2020
Authorized
shares 10.41M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1737927 CUSIP 138035704 13F (30d) 205 filings 154 filers Visit website Investor relations